Targovax strengthens focus on ONCOS oncolytic virus development program
Recent clinical data is driving increased interest in the industry for oncolytic viruses as an emerging class of cancer therapeutics Development of Targovax lead product, ONCOS-102, to be prioritized in mesothelioma as launch indication as well as checkpoint inhibitor combinations in cold tumors---------------------------------------------------------------------- Conference call The company will host a conference call which will include a Q&A session. CEO Øystein Soug, CMO Magnus Jäderberg and CFO Erik Digman Wiklund will host the conference call. Call in details can be found